Legislation & Regulation
Richard Mark Kirkner

Katie Holcomb

It seems like Godot may arrive sooner. Seven years after the biosimilar law was enacted, stakeholders are losing patience with the FDA.
Ed Silverman

A Harvard Law School group is among those that have taken action.

Richard G. Stefanacci, DO
Scott Guerin, PhD

Managed care organizations need to work on several fronts if they are to improve patient adherence. Limiting out-of-pocket costs is one place to start.

Tomorrow’s Medicine
Thomas Morrow, MD

Sarepta’s eteplirsen functions like an RNA patch so functioning dystrophin gets made. Other drugs like it may be used to treat Ebola and other viral infections.

Biologics in Development
Katherine T. Adams
Cancer Watch
Peter Wehrwein
Organized oncology isn’t ready to give up on ASP+6 payment for Medicare Part B drugs. But experimentation with value-based pricing has some supporters.

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report